{"denomUnitsSelected":"Participants","description":"MRD assessment will be correlated between flow cytometry (MPF) and NGS. Patients will be categorized as positive vs. negative MRD for each measure. The number of patients who have agreement between the 2 measures (both positive or both negative) will be assessed.","reportingStatus":"NOT_POSTED","timeFrame":"Up to cycle 18/16 months of treatment","title":"MRD Assessed Using Flow Cytometry (MPF) and Next Generation Sequencing (NGS)","type":"OTHER_PRE_SPECIFIED"}